|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Arizona |
|---|---|
| Collaborator: |
GlaxoSmithKline |
| Information provided by: | University of Arizona |
| ClinicalTrials.gov Identifier: | NCT00752167 |
Purpose
We hypothesize that exercise-induced bronchospasm (EIB) at the NCAA Division I collegiate level is over diagnosed, while poorly controlled asthma resulting in exercise-related symptoms in this same population may be under diagnosed, being erroneously attributed to EIB. This project will test individuals self-identified as having exercise induced bronchospasm or asthma, as well as gender-matched controls from the same sport, with eucapnic voluntary hyperventilation to assess for the presence of EIB or asthma. By making the correct diagnosis, improved health outcomes may be achieved and athletic performance may be enhanced.
| Condition |
|---|
|
Exercise Induced Bronchospasm, Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Diagnosis of EIB and Asthma in NCAA Division I Athletes |
| Estimated Enrollment: | 75 |
| Study Start Date: | February 2007 |
| Groups/Cohorts |
|---|
|
Case
all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
|
|
Control
control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
NCAA Varsity Division I athletes attending the University of Arizona
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: David Millward, MD | 520-626-6363 | millward@msu.edu |
| Contact: Mark A Brown, MD | 520-626-7780 | mabrown@arc.arizona.edu |
| United States, Arizona | |
| University of Arizona | Recruiting |
| Tucson, Arizona, United States, 85724 | |
| Contact: David Millward, MD 520-626-6363 millward@msu.edu | |
| Sub-Investigator: Mark A Brown, MD | |
| Principal Investigator: David Millward, MD | |
| Sub-Investigator: Stephen Paul, MD | |
| Sub-Investigator: Donald Porter, MD | |
| Sub-Investigator: Michael Stilson, MD | |
More Information
| Responsible Party: | David Millward, MD, University of Arizona |
| ClinicalTrials.gov Identifier: | NCT00752167 History of Changes |
| Other Study ID Numbers: | GSK 110189 |
| Study First Received: | September 11, 2008 |
| Last Updated: | September 12, 2008 |
| Health Authority: | United States: Institutional Review Board |
|
exercise induced bronchospasm asthma athlete |
sports eucapnic voluntary hyperventilation albuterol |
|
Asthma Bronchial Spasm Asthma, Exercise-Induced Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive |
Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
